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How do I treat canine 
superficial pyoderma 
topically?
Superficial pyoderma is a common 
diagnosis in dogs with a prevalence of up 
to 10-20% of all dogs presented in private 
practices; the condition is often recurrent 
and causes varying degrees of pain and 
pruritus depending on the extent of 
lesions (Hillier et al., 2014). Superficial 
bacterial folliculitis, bullous impetigo 
and exfoliative pyoderma associated-
epidermal collarets are the three main 
manifestations of superficial pyoderma 
in dogs (Banovic et al., 2017a). These 
conditions are frequently recurrent and 
difficult to treat due to the worldwide 
emergence of methicillin-resistant strains; 
Staphylococcus (S.) pseudintermedius is the 
principal pathogen and S. schleiferi strains 
recently has been recognized as another 
causative agent (Hillier et al., 2014).
Patients with canine atopic 
dermatitis exhibit frequent, sometimes 
recurrent, staphylococcal and yeast skin 
infections, which can exacerbate pruritus 
and dermatitis; therefore, patients 
predisposed to secondary staphylococcal 
pyoderma should be considered and 
screened for canine atopic dermatitis 
(Olivry et al., 2010; Hillier et al., 2014). 
With the emergence of multi-
drug resistant bacteria-including 
Staphylococcus species-that are important 
to human beings and companion 
animals, topical antimicrobials have 
gained popularity as an alternative to 
systemic antibiotics (Olivry et al., 2010; 
Mueller et al., 2012). Topical treatment is 
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an effective primary option for focal and 
generalized superficial pyoderma; topical 
therapy decreases bacterial counts and 
reduces surface colonization of bacteria, 
thus helping to prevent or reduce the 
incidence of recurrences. Furthermore, 
topical therapy is safer and achieves 
higher antimicrobial concentrations 
compared with systemic antibiotics 
(Olivry et al., 2010).
What is an effective active antiseptic 
ingredient?
Multiple products from numerous 
manufacturers are available for use 
in veterinary medicine with many 
companies relying on in vitro data to 
support the active ingredient choices 
(Olivry et al., 2010; Mueller et al., 2012). 
However, there is a lack of in vivo efficacy 
and comparative studies for most of 
these products. Thus, it is recommended 
that products should be selected based 
on evidence based medicine and 
randomized blinded clinical studies. 
In 2012, a review of topical therapies 
concluded that the best evidence of 
efficacy in cases of canine pyoderma 
exists with antiseptic products 
containing either chlorhexidine or 
benzoyl peroxide (Banovic et al., 
2017a). Furthermore, a recent published 
study comparing the efficacy of topical 
chlorhexidine (combined shampoo and 
spray formulations both at 4%) with 
systemic amoxicillin-clavulanic acid 
for the treatment of canine superficial 
pyoderma has shown that topical 
therapy with chlorhexidine digluconate 
products alone may be as effective as 
systemic therapy with amoxicillin-
clavulanic acid (Mueller et al., 2012). 
Chlorhexidine, a bisbiguanide antiseptic, 
is most commonly used in veterinary 
dermatology at various concentrations 
(0.5%-4%) of the water soluble gluconate 
form, however, some in vitro studies have 
also indicated that a higher concentration 
of the active ingredient is not always 
more effective (Olivry et al., 2010; Mueller 
et al., 2012; Jeffers, 2013). 
Synthetic cationic polymers are 
becoming widely used in people as 
antimicrobials due to their broad-
spectrum bactericidal activities and 
high therapeutic index. Polihexanide 
(polyhexamethylene biguanide, PHMB) 
has a broad antimicrobial spectrum, 
including Gram-positive and Gram-
negative bacteria, biofilm-building 
bacteria, and fungi including Candida 
spp. (Hübner and Kramer, 2010). 
Similarly to chlorhexidine, polihexanide 
interacts with acidic, negatively charged 
phospholipids in the bacterial membrane, 
leading to increased fluidity, permeability 
and loss of integrity, followed by the 
death of the organism (Ikeda et al., 1984; 
Gilbert and Moore, 2005). The advantage 
of polihexanide is that it does not 
contain the toxic terminal chlorobenzene 
substituents like chlorhexidine (Hubner 
et al., 2010). The results of a recent 
study indicate that polihexanide has 
comparable in vitro antimicrobial efficacy 
with chlorhexidine against common 
canine pathogenic microorganisms (S. 
pseudintermedius, Pseudomonas aeruginosa) 
affecting the skin and presents a potential 
alternative agent to chlorhexidine for 
skin and wound antisepsis in veterinary 
medicine (Banovic et al., 2013). Thus, 
further antimicrobial efficacy should be 
confirmed by in vivo studies on local 
tolerability and clinical efficacy in dogs.
What method of application will best 
reach the site of infection?
There are many different topical 
antimicrobial vehicles: shampoos, sprays, 
soaks, leave-on conditioners, rinses, 
sprays, lotions, gels, creams, wipes and 
ointments (Mueller et al., 2012; Jeffers, 
2013). The most appropriate topical 
product is based on the location and 
extent of the infection. Shampoos are the 
most practical, commonly used in the 
authors’ practice and effective in cases 
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of generalized pyoderma involving the 
patient’s trunk and proximal extremities 
(Mueller et al., 2012; Jeffers, 2013; Borio 
et al., 2015). In dogs with long or thick 
coats, clipping may be required to 
improve contact at the infection site. 
Spot treatments (ointments, gels, creams) 
work best for focal/multifocal lesions 
and hairless areas; wipes are ideal for 
intertriginous areas (facial folds, lip folds, 
interdigital areas, perivulvar region); and 
sprays are beneficial for focal lesions or 
sparsely haired areas (abdomen, ventral 
thorax, axillary area) (Mueller et al., 2012; 
Jeffers, 2013).
How much contact time is required 
and how frequent should the therapy 
be applied?
For most active ingredients, a 
minimal contact time of 10 minutes is 
preferred (Mueller et al., 2012; Jeffers, 
2013; Hillier et al., 2014; Borio et al., 2015). 
The duration of contact time is based on 
in vitro data showing stronger kill against 
the most common skin pathogens, like S. 
pseudintermedius, with longer antiseptic 
time exposures. Client compliance can 
be an issue in topical therapy; when 
a medicated shampoo is used, it is 
imperative that the owner understands 
the importance of contact time before 
rinsing. Bathing should be performed 
2 to 3 times a week when used as a 
monotherapy (Mueller et al., 2012; Jeffers, 
2013; Hillier et al., 2014; Borio et al., 2015), 
frequent bathing should be continued for 
7 days past resolution of clinical signs 
associated with the infection.
Other therapies (sprays, wipes, gels, 
lotions) should ideally be applied twice 
a day until clinical resolution; these may 
be used immediately in case of pyoderma 
recurrences (Mueller et al., 2012; Jeffers, 
2013; Borio et al., 2015). It has been 
suggested that crusts associated with 
pyoderma be removed before application 
of these products. To prevent potential 
removal by the patient (licking the areas), 
the products may be applied at times 
when the patient can be distracted via 
feeding or before walks. 
In cases of canine atopic dermatitis 
and after the superficial pyoderma 
resolution, once weekly bathing should 
be continued using non-antiseptic 
moisturizing oatmeal based shampoos. 
Topical antiseptics can disrupt cutaneous 
homeostasis by nonspecific killing of 
the normal microflora. Therefore, using 
antiseptic shampoos as continuous 
indefinitely treatment on a weekly to 
biweekly basis may result in altered 
balance of the microbiota, a condition 
known as dysbiosis. This could 
predispose atopic patients to more 
recurrent flare ups. 
Are there new developments in topical 
products for superficial pyoderma?
Antimicrobial peptides (AMPs) are 
naturally occurring and predominantly 
small cationic polypeptides expressed 
by both epithelial cells and phagocytic 
leukocytes, and they possess broad-
spectrum antimicrobial activity against 
bacteria, fungi and viruses. In addition, 
AMPs can promote chemotaxis and 
wound healing (Jenssen et al., 2006). In 
the case of skin infection, antimicrobial 
peptide expression in the skin is 
upregulated due to increased synthesis 
by keratinocytes and deposition from 
degranulation of recruited neutrophils 
(Braff et al., 2005). Recently, a new 
shampoo (ICF Peptivet shampoo, 
Cremona, Italy) containing AMP2041 
antimicrobial peptide was released on 
the market. The product shows fast and 
complete in vitro antimicrobial activity 
against a panel of bacterial and fungal 
strains involved in canine cutaneous 
infections (Ghibaudo et al., 2016). 
However, these antimicrobial assays have 
been performed under non-physiological 
conditions, using bacterial growth media 
rather than a culture environment that 
closely resembles canine skin. Further 
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in vivo studies are needed to evaluate 
if this very promising product is able to 
contribute to the decrease of systemic 
antibiotics for superficial pyoderma in 
clinical practice.
Diluted bleach (a.k.a. sodium 
hypochlorite hereafter referred to 
solely as “hypochlorite”) represents 
an inexpensive and widely available 
topical antiseptic. Dilute bleach baths 
(to an approximate concentration of 
0.005% hypochlorite) have been shown to 
remarkably reduce the severity of infected 
atopic dermatitis (AD) in children over 3 
months duration (Huang et al., 2011). 
The author of a recent review on 
the therapeutic approach for canine 
superficial pyoderma recommended the 
application of 0.06–0.12% diluted sodium 
hypochlorite solution, two to four times 
weekly, as an adjunctive topical therapy 
for this disease (Bloom, 2014). However, 
the recommendation for this dilution 
range was based solely on personal 
clinical experience. Given the lack of 
evidence for diluted bleach usage in dogs, 
our initial study revealed excellent in vitro 
antimicrobial effectiveness of diluted 
sodium hypochlorite against isolates of 
S. pseudintermedius, P. and Malassezia (M.) 
pachydermatis from atopic dogs (Banovic 
and Lemo, 2014). Furthermore, we 
evaluated the antiseptic efficacy and local 
side effects of a single 0.05% and 0.005% 
diluted bleach solution application on 
the skin of healthy dogs (Banovic et 
al., 2017b). The single application at 
both concentrations revealed excellent 
tolerability as well as reduction in 
bacterial load evaluated using contact 
agar plates with neutralization medium. 
We followed with a repeated diluted 
bleach baths (0.005%) study in healthy 
dogs; twice weekly bleach baths for 15 
minutes were safe and there was no signs 
of skin irritation or dryness in any dog 
(Banovic, unpublished data). 
Interestingly, there was no change 
staphylococcal diversity and skin 
microbiome evaluated through bacterial 
16S rRNA gene sequencing (Banovic, 
unpublished data). Further research is 
needed to evaluate how bleach baths 
modulate skin barrier function and 
reduction in itch intensity in atopic dogs. 
An alternative to bleach soaks may be a 
0.011% hypochlorous acid containing 
solution (Veterycn, VF; Innovacyn, Rialto, 
CA, USA) marketed for topical treatment 
in veterinary medicine. However, a recent 
pilot study evaluating this product failed 
to demonstrate efficacy in treating canine 
pyoderma when used twice a day for 3-4 
weeks (Udenberg et al., 2015).
Which topical antibiotics should I use 
for canine pyoderma?
Topical therapy with fusidic acid is an 
attractive alternative to systemic therapy 
based on low minimum inhibitory 
concentrations documented in canine 
pathogenic staphylococci, including 
strains MRSP (methicillin-resistant 
Staphylococcus pseudintermedius) (Frosini 
et al., 2017). Recent studies suggest that 
topical fusidic acid products should be 
useful in the treatment of canine surface 
and superficial pyoderma (intact follicles) 
caused by bacteria susceptible to fusidic 
acid, in countries where it is available, 
but not deep pyoderma (where infection 
extends to surrounding dermis) (Frosini 
et al., 2017).
Mupirocin, an antibiotic developed 
from the fermentation of Pseudomonas 
fluorescens (Godbeer et al., 2014), 
Mupirocin is a bacteriostatic antibiotic 
that reversibly binds to isoleucyl tRNA 
synthetase to disrupt protein synthesis 
and is widely used to eliminate 
nasal carriage of methicillin-resistant 
Staphylococcus aureus (MRSA) in human 
MRSA carriers (Godbeer et al., 2014). 
Mupirocin has been used only on a 
limited basis in veterinary medicine but 
is approved in the United States for the 
treatment of bacterial skin infections and 
superficial pyoderma in dogs.
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Silver sulfadiazine cream can be 
very useful in the treatment of localized 
pyoderma with Pseudomonas spp. Silver 
salts precipitate proteins and interfere 
with bacterial metabolic activities 
(Rosenkrantz, 2006). It has been shown to 
be effective in vitro against Pseudomonas 
at concentrations ranging from 0.1 to 1% 
(Rosenkrantz, 2006). 
How do I treat Malassezia 
dermatitis topically?
Malassezia yeasts are normally com-
mensal species found primarily in the skin 
and ears of dogs (Rosenkrantz, 2006; Ol-
ivry et al., 2010). Similar to bacterial pyo-
derma, Malassezia dermatitis is frequently 
a recurrent skin infection associated with 
an underlying disease process such as 
atopic dermatitis (Rosenkrantz, 2006; Ol-
ivry et al., 2010). Topical therapy is useful 
in eliminating infection and reducing the 
yeast numbers (Bond et al., 1995; Rosen-
krantz, 2006; Olivry et al., 2010). For gen-
eralized infections, shampoo therapy is 
most useful, while localized infections 
may benefit from creams, lotions, wipes 
and sprays. There are numerous commer-
cially available shampoo formulations for 
treatment of Malassezia dermatitis, how-
ever, there is only strong evidence based 
on clinical study for use of topical micona-
zole/chlorhexidine shampoo treatment 
(Malaseb, Bayer HealthCare LLC Animal 
Healthy Division, KS, USA; twice a week 
for 3 weeks) (Bond et al., 1995) and, in se-
vere cases, systemic treatments with azole 
derivatives (ketoconazole, itraconazole, 
terbinafine). Frequent use of systematic 
antifungals is not recommended because 
it is may be associated with increased 
prevalence of drug resistance.
Topical therapy for seborrheic 
skin diseases
Antiseborrheic shampoos function by 
restoring and normalizing keratinocyte 
turnover. These agents work in two 
different ways:
 ₋ a cytostatic effect is exerted on basal 
cells, thereby reducing their rate of 
division (keratoplastic).
 ₋ elimination of excess corneal cells, 
by increasing desquamation. Most 
antiseborrheic shampoos also 
eliminate excess corneal layers, by 
increasing desquamation. This is 
thought to be a result of ballooning 
of corneocytes that makes the 
stratum corneum softer and reduces 
the intercellular cohesion of the 
corneocytes and results in increased 
desquamation. Agents that function 
in this way are called keratolytic 
(Rosenkrantz, 2006).
There are many keratoplastic and 
keratolytic agents that are commercially 
available in shampoo formulations. 
Salicylic acid is a keratolytic agent that 
reductes skin pH which leads to an 
increase in the amount of water that 
keratin is able to absorb (Rosenkrantz, 
2006). Stratum corneum hydratation 
increases and corenal layer softens which 
allows desquamation. Salicylic acid 
acts synergistically with sulphur, and 
is often present in small quantities in 
shampoos (Rosenkrantz, 2006). Sulphur 
is mildly keratolytic and has numerous 
other, mainly antiseborrhoeic, properties. 
It is also keratoplastic, due to a direct 
cytostatic effect and possibly because 
it interacts with epidermal cysteine to 
form cystine, an important component 
of the corneal layer (Rosenkrantz, 2006). 
It exerts synergistic activity with salicylic 
acid. This synergism appears optimal 
when both substances are incorporated 
into the shampoo in equal concentrations 
(Rosenkrantz, 2006). Selenium disulphide 
is keratolytic and keratoplastic by 
reducing epidermal turnover and 
impairing disulphide bridge formation 
in keratin. It is also antiseborrhoeic 
but also has irritant and drying effects. 
Phytosphingosine is a proceramid 
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(ceramides are components of the extra 
cellular sheets of lipids in the stratum 
corneum) and a natural component of the 
epidermis, with anti-inflammatory and 
antimicrobial effects. 
Benzoyl peroxide, in addition to 
being antibacterial, is antiseborrhoeic, 
by hydrolyzing sebum and reducing 
sebaceous gland activity (Rosenkrantz, 
2006). The skin may also become dry 
and moisturizers are therefore always 
indicated after using this product.
How to use shampoos in 
keratoseborrhoeic disorders?
Shampoos should initially be applied 
several times a week (Rosenkrantz, 2006). 
With time, frequency of application 
can gradually be reduced to give the 
longest interval over which treatment 
is still effective, usually about 2 weeks. 
Cases should be monitored frequently. 
The therapeutic agent often needs to be 
changed following the development of 
side effects, rebound effects or change in 
clinical presentation. 
The more severe the dermatitis is, 
the more active and potent the shampoo 
must be and the more frequent will 
be the applications. For mild and/
or pityriasiform keratoseborrhoeic 
disorders, keratolytic agents should 
be selected whereas for severe and/or 
psoriasiform disorders, keratoregulating 
(keratoplastic) agents will also be 
used (Rosenkrantz, 2006). In all cases 
but particularly in greasy seborrhea, 
antiseborrhoeic agents may be useful.
Concept of “proactive therapy” with 
topical steroids in canine atopic 
dermatitis
Canine atopic dermatitis is a common 
skin disorder in small-animal practice and 
is defined as a hereditary predisposition 
to develop pruritic inflammatory skin 
disease associated with IgE antibodies, 
which typically target environmental 
allergens (Olivry et al., 2010). Topical 
steroids have an anti-inflammatory effect 
and represent the mainstay of therapy for 
bringing human atopic dermatitis under 
control (Wollenberg et al., 2008). Reactive 
treatment (only when skin lesions 
develop) with topical steroids following 
the presence or absence of visible lesions 
was the traditional mainstay of AD 
treatment in humans (Wollenberg et al., 
2008). This strategy is well established 
with good short-term results; however, it 
is difficult to achieve long-term remission 
between flares, because the normal-
looking non-lesional skin of patients 
with AD is not normal (Wollenberg et 
al., 2008). Proactive therapy is defined as 
the low-dose, intermittent application of 
anti-inflammatory therapy to previously 
affected skin; this approach targets 
invisible inflammation in the usually 
relapsing ‘problem zones’ of patients 
with AD (Wollenberg et al., 2008). Topical 
steroids are divided into VII classes of 
potency, from low (class VII) to high (class 
I) (Jacob and Steele, 2006). The clinical 
efficacy and the risk of local (e.g. skin 
thinning, comedones and alopecia) and 
systemic (i.e. hypothalamus-pituitary axis 
suppression due to systemic absorption) 
side effects correlate with potency class 
and duration of use and frequency of 
application (Rosenkrantz, 2006). 
As suggested in human AD 
(Wollenberg et al., 2008), clearing the skin 
lesions with daily application of steroids 
for 1-2 weeks should be followed with the 
intermittent use of the same product (e.g. 
2-3 times/week) even if visible lesions 
have disappeared. This “proactive 
treatment” approach reduces the risk of 
flares and extends the time of remission. 
The long-term proactive application of 
hydrocortisone aceponate (Cortavance, 
Virbac) spray administered on two 
consecutive days each week or twice 
weekly was shown to be effective and 
well-tolerated in atopic dogs with skin 
and recurrent ear infections, prolonging 
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remission times of flares in comparison 
with reactive therapy (therapy only when 
clinical signs are visible) (Lourenco et al., 
2016). 
Improving epidermal barrier 
dysfunction in canine atopic 
dermatitis
The complex process of epidermal 
differentiation is disturbed in canine 
atopic dermatitis lesions, and the 
impaired skin barrier offers potential 
targets for therapeutic intervention, such 
as fatty acids (oral supplements or topical 
solutions) and various topical treatments 
(Olivry et al., 2010; Olivry et al., 2015). 
Weekly bathing with a mild nonirritating 
shampoo and postbathing topical 
moisturizers are recommended for each 
patient; this therapy provides a direct 
soothing effect to the skin, physically 
removes surface allergens, and increases 
skin hydration (Olivry et al., 2010; Olivry 
et al., 2015). 
According to the systematic review 
of clinical trials, essential fatty acid 
supplementation is indicated only for 
long-term management of canine atopic 
dermatitis as an adjunctive treatment 
(Olivry et al., 2010; Olivry et al., 2015) 
the clinical benefit of essential fatty acid 
supplements on the skin may take up 
to 2 months to be seen. In recent years, 
some topical (spot-on, spray, shampoo, 
emulsion) formulations containing 
fatty acids and ceramides have been 
introduced for dogs with canine atopic 
dermatitis; however, their efficacy is 
inconsistent, and veterinarians should 
weigh their benefit and cost before 
deciding to use them (Olivry et al., 2010; 
Olivry et al., 2015).
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Topikalna terapija u veterinarskoj dermatologiji
Frane BANOVIĆ, dr. med. vet., College of Veterinary Medicine, University of Georgia, 
Athens, GA, USA; dr. sc. Nikša LEMO, dr. med. vet., redoviti profesor, Veterinarski fakultet 
Sveučilišta u Zagrebu, Zagreb, Hrvatska
Topikalna ili lokalna terapija iznimno 
je važna u liječenju alergijskih, infektivnih 
i seboroičnih bolesti kože. Veterinarima su 
dostupne brojne komercijalne formulacije i 
mogu uključivati različite aktivne sastojke. 
Koža pasa često je osjetljivija od ljudske kože 
zbog anatomskih i fizioloških posebitosti, 
uključujući i razlike u debljini rožnatog sloja, 
pH kože i gustoće dlačnih folikula koji mogu 
također olakšati prodiranje aktivnih sastojaka 
lokalne terapije. Stoga je preporučljivo 
koristiti formulacije registrirane „samo za 
primjenu u pasa.“ U ovom preglednom 
članku naglašava se primjena lokalne 
terapije za liječenje površinske upale kože, 
keratoseboroičnih poremećaja i atopijskog 
dermatitisa u pasa.
Ključne riječi: lokalna terapija, površinska 
upala kože, keratoseboroične bolesti, atopijski 
dermatitis
